During the past 12 months, Scinai Immunotherapeutics's average Total Assets Growth Rate was -8.10% per year.
During the past 3 years, the average Total Assets Growth Rate was -5.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 7.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 30.60% per year.
During the past 13 years, Scinai Immunotherapeutics's highest 3-Year average Total Assets Growth Rate was 74.70%. The lowest was -11.80%. And the median was 20.85%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinai Immunotherapeutics Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Scinai Immunotherapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinai Immunotherapeutics (NAS:SCNI) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Sep. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Scinai Immunotherapeutics's Asset Turnover for the quarter that ended in Sep. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Scinai Immunotherapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCNI has been successfully added to your 